BI 907828
1 product
5 abstracts
Abstract
Treatment of patients with dedifferentiated liposarcoma (DDLPS) with the MDM2–p53 antagonist brigimadlin and p53 function: A longitudinal analysis of circulating microRNAs (miRNAs) in a first-in-human phase Ia/Ib study.Org: Boehringer Ingelheim Pharma GmbH & Co. KG, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical Center, National Cancer Center Hospital East, Kashiwa, Japan, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Maria Skłodowska-Curie National Research Institute of Oncology, Kraków, Poland,
Abstract
A phase 0/Ia study of BI 907828 concentrations in brain tissue and a nonrandomized, open-label, dose escalation study of BI 907828 in combination with radiotherapy in patients with newly diagnosed glioblastoma (GBM).Org: Mayo Clinic, Rochester Regional Health System, MN, Jacksonville, Flare Therapeutics,
Abstract
A phase IIa/IIb, open-label trial of BI 907828, an MDM2–p53 antagonist, in patients with locally advanced/metastatic biliary tract carcinoma or pancreatic ductal adenocarcinoma: Brightline-2.Org: Boehringer Ingelheim (People’s Republic of China) Investment Co., Ltd., Boehringer Ingelheim Pharmaceuticals, Inc., Boehringer Ingelheim International GmbH,
Abstract
Longitudinal mutational analysis of TP53 in plasma circulating tumor DNA (ctDNA) in patients (pts) with solid tumors in a phase I study of BI 907828, an MDM2–p53 antagonist.Org: Boehringer Ingelheim Pharma GmbH & Co. KG, Memorial Sloan Kettering Cancer Center, National Cancer Center Hospital East, Kashiwa, Japan, Sarah Cannon Research Institute/Tennessee Oncology, Florida Cancer Specialists & Research Institute,
Abstract
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients (pts) with solid tumors: Safety and efficacy in patients with dedifferentiated liposarcoma (DDLPS).Org: Yale University School of Medicine, Yale Cancer Center, Yale School of Medicine, New Haven, CT, Memorial Sloan Kettering Cancer Center, Department of Experimental Therapeutics, National Cancer Center Hospital East, Sarah Cannon Research Institute/Tennessee Oncology,